The NHS is facing a crisis as patients with ADHD, who initially sought private care, are now returning to the public system, exacerbating already lengthy waiting lists. But why is this happening?
The issue lies in the complex relationship between the NHS and private healthcare providers. Patients referred by their GPs to private clinics, funded by the NHS, are finding themselves in a bind. While private clinics may diagnose ADHD, they often fall short of adhering to the National Institute for Health and Care Excellence (NICE) guidelines. This non-compliance can lead to a lack of qualified staff to support ongoing prescription needs.
And here's where it gets controversial: patients are facing the harsh reality of prescription costs exceeding £200 per month when GPs terminate shared care agreements with private clinics. This sudden shift can have devastating consequences, as illustrated by the father of a young man who relied on medication to manage his ADHD symptoms and maintain a stable life.
The Midlands Partnership University NHS Foundation Trust (MPFT) has admitted that the influx of patients returning from private care is overwhelming their capacity. This trend is not only lengthening waiting lists but also reducing the ability to handle new and complex cases, potentially leading to delays and gaps in care.
The Guardian's investigation revealed that the NHS is overspending on ADHD services, with a significant portion going to unregulated private assessments. As demand for assessments surges, NHS services are struggling to keep up, leaving over half a million people awaiting assessment.
Health Secretary Wes Streeting conceded that the government is failing to manage the surge in autism and ADHD referrals. To address this, the NHS is outsourcing assessments and treatment to private providers, utilizing the 'right to choose' pathway. However, this system is fragmented and lacks consistent clinical standards, as evidenced by a letter from MPFT, which highlighted the challenges faced by patients.
The letter, written in response to a patient's withdrawal from a shared care agreement, emphasized the distress caused by the sudden cessation of prescribing. It also shed light on the limitations of the 'right to choose' pathway, where patients may select providers who can diagnose but not prescribe medication.
The lack of regulation surrounding private ADHD providers is a growing concern. Private clinics can set up services and offer ADHD diagnoses, but their assessments may not meet NICE guidelines, and they may struggle to provide adequately skilled staff for prescribing.
As the NHS grapples with this complex issue, it raises questions about the balance between public and private healthcare. How can we ensure patients receive consistent, high-quality care without facing financial burdens or treatment disruptions? The debate is open, and your insights are welcome.
